FIGURE 3. Prognosis and accuracy evaluation of the signature. (A) Survival analysis in the training cohort. Patients in high-risk group had a worse prognosis. (B) Survival analysis in the internal validation cohort. Patients in the high-risk group had a significantly worse prognosis. (C)ROC curve of training cohort. The AUC values in 1, 2, 3, 4, and 5 years of the signature were 0.768, 0.765, 0.749, 0.739, and 0.759, respectively. (D) The AUC values of internal validation cohort in 1, 2, 3, 4, and 5 years were 0.692, 0.649, 0.671, 0.723, 0.740, respectively (***p < 0.001).